Cost-utility Analysis of Atezolizumab Combined with Standard Chemotherapy Regimen in the First-line Treatment of Extensive-stage Small-cell Lung Cancer / 中国药房
China Pharmacy
;
(12): 77-81, 2021.
Article
in Chinese
| WPRIM
| ID: wpr-862269
ABSTRACT
OBJECTIVE:To evaluate the economics of atezolizumab combined with stardard chemotherapy regimens versus chemotherapy regimens alone as first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC)from the healthcare system perspective. METHODS :A partitioned survival model was constructed using published phase Ⅲ clinical trial data (IMpower133)and literature data to evaluate the economics of atezolizumaba combined with standard chemotherapy regimens versus chemotherapy regimens alone as first-line treatment for ES-SCLC. One-way sensitivity analysis and probabilistic sensitivity analysis were used to evaluate the stability of the results. RESULTS :The results of cost-utility analysis showed that the cost of atezolizumab combined with chemotherapy group was 489 598.52 yuan,with utility of 0.70 QALYs;the cost of chemotherapy alone group was 126 276.80 yuan,with utility of 0.55 QALYs;the incremental cost-utility ratio (ICUR)between the two groups was 2 361 709.05 yuan/QALY,far exceeding the willingness-to-pay (WTP)in China (3 times of GDP per capita in 2019,212 676 yuan). One-way sensitivity analysis showed that progression-free utility value of atezolizumab combined with chemotherapy had the greatest impact on the results of cost-utility analysis ;probabilistic sensitivity analysis suggested that the atezolizumab combined with chemotherapy regimen was not economical within the WTP range of 0-500 000 yuan/QALY. CONCLUSIONS :Atezolizumab combined with chemotherapy regimen has no cost-utility advantage versus chemotherapy alone in the first-line treatment of ES-CLC under the current economic level of China.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Health economic evaluation
Language:
Chinese
Journal:
China Pharmacy
Year:
2021
Type:
Article
Similar
MEDLINE
...
LILACS
LIS